Impact of Resveratrol on Fasting Glucose and Insulin Levels in Type 2 Diabetes
Introduction to Resveratrol
Resveratrol, a polyphenol primarily found in the skins of red grapes, has gained attention for its potential health benefits. This potent antioxidant is recognized for its anti-inflammatory, anti-cancer, anti-aging, and cardioprotective properties. While some studies suggest that resveratrol may enhance insulin sensitivity in diabetic rats and individuals with type 2 diabetes mellitus (T2DM), findings have been inconsistent.
Review of Current Research
A recent review aimed to clarify these inconsistencies by analyzing data from past randomized control trials. The findings of this comprehensive analysis were published in the journal Nutrition and Metabolism. The review included nine randomized clinical trials with a total of 283 participants diagnosed with T2DM.
Study Parameters and Findings
All studies tracked fasting plasma glucose levels, with some also monitoring glycated hemoglobin (HbA1c), insulin resistance, systolic and diastolic blood pressure, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and insulin concentrations. The daily resveratrol doses ranged from 8 milligrams to 3000 milligrams and were administered over periods varying from four weeks to twelve months.
The pooled analysis revealed that resveratrol significantly reduced fasting plasma glucose levels in T2DM patients compared to the control group. Notably, patients receiving high doses of resveratrol exhibited a significant decline in fasting plasma glucose, while those on lower doses did not experience any reduction.
Glycated Hemoglobin and Insulin Resistance
Glycated hemoglobin (HbA1c) serves as a critical indicator of blood glucose levels over the preceding six to eight weeks, unaffected by daily fluctuations. Among the nine studies reviewed, six provided data on HbA1c levels, encompassing 228 patients. The analysis indicated that HbA1c levels remained unchanged with resveratrol intake.
Conversely, data on insulin resistance, drawn from five trials involving 153 patients, demonstrated a significant improvement in insulin sensitivity with resveratrol supplementation. The analysis also indicated reductions in insulin levels, as well as systolic and diastolic blood pressure, although LDL-c and HDL-c levels showed no significant changes. Specifically, high doses (over 100 milligrams/day) were effective in lowering glucose levels, while low doses (under 100 milligrams/day) were ineffective.
Study Limitations and Future Research
One of the notable limitations of the review was the variation in forms of resveratrol used (extracts and powders) and the differences in dosage and duration across studies. These factors may influence the conclusions drawn, highlighting the need for larger-scale studies to better understand the dose-dependent effects of resveratrol.
Conclusion
Overall, the findings suggest that resveratrol intake may improve glycemic control in individuals with type 2 diabetes mellitus. Current antidiabetic agents, including insulin, biguanides, sulfonylureas, α-glucosidase inhibitors, and DPP-4 inhibitors, often come with limitations related to contraindications or side effects such as hypoglycemia and weight gain. Some research indicates that resveratrol, at doses up to 1 gram per day, does not exhibit toxic effects. While further validation through larger trials is necessary, resveratrol may offer a promising alternative for managing type 2 diabetes mellitus.
References
1. Méndez-del Villar M, et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014 Dec;12(10):497-501. doi: 10.1089/met.2014.0082. Epub 2014 Aug 19. PubMed PMID: 25137036.
2. González-Rodríguez Á, et al. Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner. Mol Nutr Food Res. 2015 Aug;59(8):1431-42. doi: 10.1002/mnfr.201400933. Epub 2015 Apr 28. PubMed PMID: 25808216.
3. Lee YE, et al. Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One. 2012;7(11):e50412. doi: 10.1371/journal.pone.0050412. Epub 2012 Nov 30. PubMed PMID: 23226280; PubMed Central PMCID: PMC3511555.
4. Bo S, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016 Sep;111:896-905. doi: 10.1016/j.phrs.2016.08.010. Epub 2016 Aug 9. PubMed PMID: 27520400.
5. Thazhath SS, et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am J Clin Nutr. 2016 Jan;103(1):66-70. doi: 10.3945/ajcn.115.117440. Epub 2015 Nov 25. PubMed PMID: 26607942.
6. Zhu X, et al. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr & Metab. 2017 Sept;14:60. doi: 10.1186/s12986-017-0217-z.
7. Movahed A, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267. doi: 10.1155/2013/851267. Epub 2013 Sep 1. PubMed PMID: 24073011; PubMed Central PMCID: PMC3773903.